Histotripsy-initiated immune response synergizes with chemotherapy in a neuroblastoma murine model

Key Points

• Histotripsy drives a systemic antitumor immune response, reshaping the tumor microenvironment.
• The combination of histotripsy and chemotherapy leads to improved treatment outcomes in this model.
• Assessment using a syngeneic neuroblastoma model demonstrates significant therapeutic synergy.
• This approach highlights the potential for more effective cancer treatments, warranting further exploration across studies.

Abstract